Article ; Online: Follicle-stimulating hormone promotes growth of human prostate cancer cell line-derived tumor xenografts.
2021 Volume 35, Issue 4, Page(s) e21464
Abstract: Chemical castration in prostate cancer can be achieved with gonadotropin-releasing hormone (GnRH) agonists or antagonists. Their effects differ by the initial flare of gonadotropin and testosterone secretion with agonists and the immediate pituitary- ... ...
| Abstract | Chemical castration in prostate cancer can be achieved with gonadotropin-releasing hormone (GnRH) agonists or antagonists. Their effects differ by the initial flare of gonadotropin and testosterone secretion with agonists and the immediate pituitary-testicular suppression by antagonists. While both suppress luteinizing hormone (LH) and follicle-stimulating hormone (FSH) initially, a rebound in FSH levels occurs during agonist treatment. This rebound is potentially harmful, taken the expression of FSH receptors (R) in prostate cancer tissue. We herein assessed the role of FSH in promoting the growth of androgen-independent (PC-3, DU145) and androgen-dependent (VCaP) human prostate cancer cell line xenografts in nude mice. Gonadotropins were suppressed with the GnRH antagonist degarelix, and effects of add-back human recombinant FSH were assessed on tumor growth. All tumors expressed GnRHR and FSHR, and degarelix treatment suppressed their growth. FSH supplementation reversed the degarelix-evoked suppression of PC-3 tumors, both in preventive (degarelix and FSH treatment started upon cell inoculation) and therapeutic (treatments initiated 3 weeks after cell inoculation) setting. A less marked, though significant FSH effect occurred in DU145, but not in VCaP xenografts. FSHR expression in the xenografts supports direct FSH stimulation of tumor growth. Testosterone supplementation, to maintain the VCaP xenografts, apparently masked the FSH effect on their growth. Treatment with the LH analogue hCG did not affect PC-3 tumor growth despite their expression of luteinizing hormone/choriongonadotropin receptor. In conclusion, FSH, but not LH, may directly stimulate the growth of androgen-independent prostate cancer, suggesting that persistent FSH suppression upon GnRH antagonist treatment offers a therapeutic advantage over agonist. |
|---|---|
| MeSH term(s) | Androgens/pharmacology ; Animals ; Cell Line ; Follicle Stimulating Hormone/metabolism ; Follicle Stimulating Hormone/pharmacology ; Gonadotropin-Releasing Hormone/metabolism ; Gonadotropin-Releasing Hormone/pharmacology ; Heterografts/drug effects ; Humans ; Luteinizing Hormone/metabolism ; Male ; Mice, Nude ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/metabolism ; Receptors, FSH ; Testis/metabolism ; Testosterone/pharmacology ; Mice |
| Chemical Substances | Androgens ; Receptors, FSH ; Gonadotropin-Releasing Hormone (33515-09-2) ; Testosterone (3XMK78S47O) ; Luteinizing Hormone (9002-67-9) ; Follicle Stimulating Hormone (9002-68-0) |
| Language | English |
| Publishing date | 2021-04-16 |
| Publishing country | United States |
| Document type | Journal Article ; Research Support, Non-U.S. Gov't |
| ZDB-ID | 639186-2 |
| ISSN | 1530-6860 ; 0892-6638 |
| ISSN (online) | 1530-6860 |
| ISSN | 0892-6638 |
| DOI | 10.1096/fj.202002168RR |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 2266: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
|||
| Zs.MO 296: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.